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Abstract
The technique was emanated in early 1960s; nowadays, deep brain stimulation 
(DBS) has become a huge practice in treatment of various movement disorders along 
with some psychiatric disorders. The advancement of DBS in different neurodegen-
erative diseases and managing patients with refractory brain disorders are closely 
related to the developments in technology. This development in regard with the 
device advancement along with the safe coupling of DBS to high-resolution imaging 
can help us to shape our knowledge in brain-wide networks and circuits linked with 
clinical aspects. DBS is found to be useful in learning and memory. On the contrary, 
traditional epilepsy surgeries are more complicated and technologically DBS is 
easier and more feasible. There are mild adverse effects of this DBS treatment, but a 
number of studies have shown positive treatment outcome with movement disorders 
and many kinds of psychiatric disorders too.
Keywords: deep brain stimulation, neuromodulation, brain, movement disorder, 
neurodegenerative disease, psychiatric disorder
1. Introduction
Neuromodulation is an increasingly rising field in the successful treatment of 
neurological disorders [1, 2]. Neurostimulation allows highly flexible alteration 
of disease symptoms. A number of medications fail due to severe side effects that 
outweigh the medication benefit, but neurostimulation has been so long to be 
potentially used as a treatment option for several movement disorders [2], with 
mild side effects with unknown mechanism of action in other disorders [3].
2. Types of Neuromodulation techniques
1. Deep brain stimulation (DBS) is an approved option for the treatment of 
intractable forms of various diseases. It involves inflecting the dysfunc-
tional neuronal networks by long-term electrical stimulation, which utilizes 
implanting electrodes placed in the target neurological site that excites the 
neuronal circuits [4]. In recent years, evolution of DBS has revolutionized the 
treatment few neurological diseases especially in the treatment of movement 
disorders [5].
2. Vagal nerve stimulation (VNS) uses a device to stimulate the vagus nerve via 
electrical impulses. VNS is very helpful for people who have not responded to 
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intensive antiepileptic drug treatment and suffers from their adverse effects. 
FDA has approved VNS in 1997 for the treatment of epilepsy, depression, and 
various other disorders.
3. Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation 
by producing electrical impulses at a specific area of the brain through electro-
magnetic induction or by changing magnetic field [6].
4. Spinal cord stimulation (SCS) is useful in the treatment of long-lasting 
pain, which utilizes a stimulator that gives an electrical stimulus to the 
spinal cord.
5. Epidural motor cortex stimulation technique is highly useful in the treatment 
of intractable long-term neuropathic pain.
6. rTMS is useful in the treatment of experimental pain, neuropathic pain, and 
nonneuropathic chronic conditions.
7. Transcranial direct current stimulation is a highly used noninvasive technique 
altering neuronal plasticity. It is moderately used in treating neuropathic pain 
and fibromyalgia [7].
3. Deep brain stimulation (DBS)
DBS is an electrode implantation method using stereotactic techniques into 
the deep regions of brain for modulating neuronal function. An implantable pulse 
generator (IPG) is attached below the clavicle region, with an intention to treat 
neurological and psychiatric conditions. This attached IPG works on battery and 
delivers electrical stimulation, which is regulated externally by patients with the 
help of the remote. The electronic components like frequency, pulse, voltage, and 
other parameters can be altered to attain maximum efficacy of the treatment. It is 
believed that it works on excitation and inhibition of neurons present nearby the 
electrodes, but the exact mechanism is still unknown.
Low-frequency stimulation seems to excite nearby neurons, while high-frequency 
stimulation may decrease local activity leading to rescindable functional lesion. 
This simple-minded opinion for the mechanistic action has been a challenge 
in recent years, and more comprehensive knowledge may promote enhanced DBS 
 treatments [8].
4. Brief chronicle of DBS
4.1 Early history
During the early 1900s’ experiments, first stereotactic frame was designed that 
allowed stimulation of deeper regions of brain. In 1947, X-ray pneumoencepha-
lography was developed that enabled surgeons to locate the target with the help of 
detailed stereotactic atlas that was developed later on. In 1950, stereotactic tech-
niques were used for the tremor treatment. Later, in 1963, Albe Fessard reported 
high-frequency (~100–200 Hz) electrical stimulation for the first time in the ven-
tral intermediate thalamic nucleus that could substantially alleviate Parkinsonian 
tremor [9].
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4.2 The last 50 years
In 1960, levodopa treatment development was highly effective for Parkinsonian 
symptoms with lesser risk and expense compared to DBS implantation and this led 
the curtailing of early forms of DBS research.
Inspite of the drawbacks, the research for use of DBSnever stopped. DBS con-
tinued to observe restricted use in intractable chronic treatment, with Medtronic 
Inc. (Minneapolis, MN, USA) and released the first fully implanted DBS systems 
commercially accessible for this purpose in the mid-1970s [10].
Other study groups investigated the use of thalamic DBS to treat consciousness 
diseases and reported few benefits. By the end of 1980s, it was evident that using 
levodopa would not hold the promising effects, after years of therapy, and patients 
developed wearing off along with the side effects like dyskinesias. Meanwhile, the 
technology of implantable medical devices had improved to the stage that it was 
routinely used for chronically implanted devices like cardiac pacemakers and spinal 
cord stimulators. The animal model study eventually got translated into clinical 
practices, and the first subthalamic nucleus (STN) DBS study got published [11]. By 
the beginning of the century, clinical use of DBS in Parkinsonian disorders has begun 
to become common [8].
5. Rationale and mechanisms of action
Although the exact mechanisms of action of DBS are still elusive in spite of 
extensive research, several theories have been put forward. These proposed mecha-
nisms can be divided according to the latency of onset of the effects from the time 
of stimulation into acute (seconds to hours) and chronic (days to months). The two 
major proposed mechanisms are as follows:
1. Electrophysiological and neurotransmitter modulation 395 likely explain the 
acute effects.
2. Plasticity and neurogenesis may explain the chronic effects [12].
However, there is a considerable overlap among the proposed mechanisms and 
one group of mechanisms has effects over the other, as described in detail in the 
following sections. Furthermore, depending on the methods used to investigate the 
mechanisms of action, different aspects of stimulation effects are tested. With an 
integrative approach combining investigations employing different modalities, one 
can understand the general effects of DBS.
5.1 Modalities used to study the mechanisms of DBS
Different methods have been used to quantify the changes produced by the 
DBS at the cellular, tissue and system levels to study the mechanisms of action of 
DBS. These modalities can be broadly classified into electrophysiological, imaging, 
biochemical, and molecular methods. Imaging techniques such as positron emission 
tomography (PET) and functional MRI (fMRI) provide information on both local- 
and system-level changes. These are complementary methods: functional imaging 
studies have high spatial resolution, whereas electrophysiological methods have 
high temporal resolution. Moreover, electrophysiological methods directly measure 
neuronal activities rather than indirect measures of neural activities using blood-
flow changes measured by imaging methods [13].
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There are several hypotheses proposed by different schools of thought, to 
explain the processes by which DBS works. Accepted and popular hypothesis 
relied on the alteration of pathological brain circuit activity induced by stimulation 
[12, 14]. The stimulating impacts that are accountable for this disturbance occur 
at protein, ionic, cellular, and network levels to produce symptom improvements 
[15]. While it is presently unclear that which of the DBS’ wide-ranging impacts 
are needed and adequate to generate therapeutic results, it is evident that high-
frequency (~100 Hz) pulse stations (~0.1 ms) produce network reactions that 
are essentially distinct from low-frequency (~10 Hz) stimulation. The electrodes 
implanted into the brain redistribute the charged particles (such as Na+ and 
Cl−ions) throughout the extracellular space, which generates electric field and 
ultimately leads to the manipulation of sodium channel protein’s voltage sensor 
embedded in the neuron membrane [16]. The opening of sodium channels at 
the cellular level may generate a potential action for initiation of axons and can 
propagate in both orthodromic and antidromic directions. DBS causes, activated 
axons are able to follow very high fidelity stimulus rates at ~100 Hz, but these high-
frequency synaptic transmissions are less robust and much complex than that of 
axonal transmission [17, 18].
Under such high-frequency activity, postsynaptic receptors can be depressed 
and axon terminals can exhaust their released pool of neurotransmitters [19, 20]. 
Even though these synapses appear to be active in DBS, theories of information 
processing suggest that they could become low-pass filters that can block low-
frequency signal transmission [21]. This general mechanism, defined as “synaptic 
filtering,” may play a crucial role in DBS, hampering the transmission of oscillatory 
activity patterns throughout the related networks of brain via neurons [22].
DBS’ simple biophysical consequences offers a background where the patterns 
of network activity observed in patients can begin to be interpreted. The oscillation 
frequency of the stimulation signal is virtually zero as stimulation intensity remains 
unchanged during DBS, which could produce what is known as an “information 
lesion” in stimulated neurons [23]. According to this theory, action potential 
induced by DBS essentially bypasses some endogenous activity directly within the 
stimulated nerves and therefore slows down the transmission of oscillatory activity 
via the network. Nonetheless, not too many researches support the statement that 
high-frequency DBS causes lesion. Research with asleep and behavioral primates 
indicates how DBS can serve as a filter, which allows certain sensorimotor-related 
regulation of neuronal activity in the activated area, whereas specifically sup-
pressing pathological low-frequency oscillation propagation [24, 25]. Certain basal 
ganglia activities, like those of reward-based decision-making or motor sequence 
learning, can often be retained during STN DBS or globus pallidus [26].
Certain factors may also have significant roles in treatment mechanism of DBS 
for PD like high-frequency DBS could provide an appropriate information lesion 
that inhibits the propagation of low-frequency oscillations, unlike low-frequency 
synchronization, could have no impact on broader network function [27, 28]. One 
of the advantages of this system is that high-frequency DBS is a standard device 
that can overcome various forms of clinical low-frequency excitations, like mobile 
tremor, dystonia, and akinesia rigidity [29].
The above proposed mechanism of DBS goes some way to explain only the acute 
effects of DBS in movement disorders, but this would not explain long-latency, 
chronic-adaptive alterations, which arise in individuals with dystonia following 
DBS and it may describe the psychological response to DBS. There might be 
possibility that low oscillating frequencies are strongly enhanced by long-term 
potentiation, while stimulation of high-frequency seems to have smaller plasticity 
effect. Therefore, replacing low-frequency patterns with high frequency can reverse 
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those symptoms associated with chronic disease [30]. DBS often takes months 
to get maximum benefit in various disorders, such as dystonia, depression, and 
epilepsy [31].
5.2 Open- vs. close-loop stimulation system
Nowadays, the open-loop system is embedded in many cases for DBS in which 
related parameters such as frequency, amplitude, and duty cycle can be adjusted by 
trained physicians. Stimulation, in this method, is fixed for initial months of treat-
ment, then later can be adjusted based on patient’s symptoms and overall conditions.
A closed-loop system receives continuous feedback from the patient’s neuronal 
circuits of brain by a present and programmed algorithm and thus appears to be 
an effective stimulation, and the parameters are adjusted real time. The implanted 
device causes physiological changes, both over long and short term, via automatic 
therapeutic parameter delivery with the ability to sense brain signals. Though 
there are no randomized controlled trials, comparing the therapeutic effect of 
open- vs. closed-loop system, few researchers opine that closed-loop method are 
more effective than the open-loop system. Through their novel closed-loop method, 
to compare the effectiveness of open-loop systems using two neurons, they dem-
onstrated that closed-loop system with implantable electrodes in GPi region has 
better results on the disease motor symptoms in PD patients than the open-loop and 
high-frequency systems [32, 33].
6. DBS in different neurodegenerative diseases
The common form of dementia, AD, treated with lesser efficiency of success in 
treatment via this technique has been used to modulate nonfunctional neuronal cir-
cuits with abnormalities seen in cortical and subcortical areas of the brain. Treatment 
helps in altering cholinesterase inhibitors and NMDA receptor antagonist [31]. DBS is 
a significant option for treatment of movement disorders that are intractable to drugs 
namely Parkinson’s disease, essential tremors, dystonia, and have recently shown to 
be effective against treatment of OCDs, depression, and Tourette syndrome [5, 31].
7. DBS in movement disorders
DBS became the standard therapy refractory over the last 25 years for individu-
als with motor circuit disabilities, most notably PD, dystonia, and essential tremor. 
DBS use has now been confined to high-income and developing countries [34]. 
Hospital-discharge-based studies of US database has showed that >30,000 DBS 
surgeries were performed during 2002 and 2011, and the publications on DBS have 
also risen over the same period of time [35].
7.1 Parkinson’s disease
Over the last 10 years, STN is used as a target for DBS in PD [36]. GPi is also 
used as a target, but the choice between STN and GPi is often guided by the bio-
medical group based on the medical context of the patient.
Multiple studies have already shown that STN DBS produces continuous 
symptom relief even after 5–10 years of treatment, although with cognition 
and gait regression due to the unremitting development of the underlying 
degenerative disorder [37]. In PD diagnosis, DBS is called the “second honeymoon” 
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(dopaminergic therapy is the first). Instability in posture and freezing can be 
improved by DBS at pedunculopontine nucleus region of the brain [38].
Based on previous studies, there is a general concept of DBS that it can improve 
PD patients with advance kind of symptoms like motor fluctuation, dyskinesias 
secondary to chronic levodopa as well as those with refractory and marked tremor. 
But based on studies of EARLYSTIM findings, DBS can also improve early stages of 
PD [39]. Due to these advantages of DBS, it is now been under clinical trials for those 
patients who are eliminated from surgery due to age factor, along with those patients 
with motor fluctuations in whom medication is effective. Due to the inherent risk of 
DBS like hemorrhage and infection, such trials face ethical issues [40].
7.2 Epilepsy
Earlier it was thought that DBS can switch open resective surgery in epilepsy, 
but after studies on DBS of the anterior nucleus of the thalamus (ANT), it was 
stifled. These researches imposed well on the efficacy of DBS but simultaneously 
also demonstrated that many patients did not attain seizure freedom after the DBS 
treatment [41, 42]. Closed-loop stimulation is a hopeful technology in epilepsy that 
can sense seizure activity with electrode and also can send electrical stimulations to 
brain to thwart propagation of seizure [43].
7.3 Essential tremor
After various studies, DBS was recommended by FDA in 1997 for the initial 
tremor symptoms of the movement disorder [44]. Along with DBS, other therapies 
such as lesional surgery have also been used for the treatment of essential tremors. 
DBS is a better choice due to its safety as well as adjustability of the stimulation, 
which is not provided by the lesional therapy [45]. Thalamic DBS is used in tremors 
of multiple sclerosis patients [46].
7.4 Dystonia
DBS had played a crucial role in dystonia treatment [47, 48]. Pallidal DBS, 
for instance, is the first-line treatment in childhood generalized dystonic dis-
ease. The most significant determinant of results was age at which surgery was 
performed and the duration of disorder [49–51]. Genetic makeup of patients 
has also been important in evaluating the outcome, as individual with DYT1 
dystonia are benefited more than the DYT6 dystonia [52]. Therefore, genetic 
testing of patients undergoing DBS treatment would suggest which candidate 
is going to be benefited more [53]. The posteroventral lateral GPi in dystonia is 
the utmost recognized target for DBS [54]. GPi stimulation offers significant 
recovery in dystonic patients with adversarial effects on low frequency. The STN 
and the thalamus are two other targets for DBS. Despite of positive outcomes 
of STN DBS, the therapeutic use is still restricted [55]. An additional important 
target is sensorimotor thalamus, which in the age of radiofrequency lesioning, 
was considered as standard target [56, 57]. The mode of action of DBS in clinical 
improvement is quite intricate because of delayed and progressive effect exhib-
ited over a period of months. The underlying mechanism for this was hypoth-
esized as the alteration of maladaptive plasticity, progressive motor learning, and 
modification in pathological oscillatory activity in basal ganglia circuitry [58]. 
Dystonia can recur within minutes to hours after discontinuation of stimula-
tion during the initial postoperative period; the advantages from stimulation 
that has been administered for several years can persist for days and weeks after 
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discontinuation [59, 60]. Therefore, DBS acts as a true treatment in case of dys-
tonia where progressive treatments are absent or poorly successful. This rationale 
has contributed an EARLYSTIM study in dystonia [61].
7.5 Alzheimer disease (AD)
AD is perhaps the most prevailing neurodegenerative disease but is character-
ized with years of gradual reduction in neurocognitive parameters. Many DBS strat-
egies have been identified for AD, including areas anterior to the fornix, entorhinal 
cortex, and the nucleus basalis of Meynert (NBM). Several studies suggest that DBS 
can affect cognitive function in AD. Nonetheless, outcome influencing factors such 
as baseline neuroanatomical substrates, surgical technique, placement of lead, and 
target population choice are the challenges for DBS [62].
8. DBS in psychiatric disorders
Psychiatric disorders are assorted conditions affecting multiple pathways with 
overlap. Such disorders have few (if any) biochemical markers that support treatment 
and outcomes, and there is a lack of data for its outcome assessment in patients. Thus, 
this affects the designing of clinical trial studies. In addition, the quality of surgi-
cal trials is also hindered due to significant selection barriers [63]. In an attempt to 
alleviate refractory psychiatric symptoms, numerous prospective studies have been 
done to evaluate if focal disruption at specific anatomic targets can impact circuit-
wide or network-wide changes. Though the strategy is enticing, there are still some 
challenges.
8.1 Tourette syndrome
Due to the behavioral and cognitive issues in these patients, less than 300 patients 
have endured DBS treatment across the world. Patients with chronic symptoms 
are improved less than those with mild symptoms as per a meta-analysis [64]. A 
randomized controlled trial in 2017 did not report any significant improvement of 
tics in Tourette syndrome patients treated with anteromedial GPi stimulation during 
the initial blinded phase of the study; however, tics improvement was documented 
during the study’s transparent period [65]. There is need of more randomized control 
trials for further development of DBS treatment in these patients.
8.2 Major depression
Major depression is a serious disorder that can impact quality of life day-to-
day working and, eventually, life expectancy significantly [66, 67]. As a result of 
advancement of imaging techniques, there is a suggestion that depression occurs 
due to alteration in mood-related circuits, which can be reversed with neuromodu-
lation along with other antidepressant therapies.
8.3 Bipolar disorder
Bipolar disorders are associated with acute and strong emotive condition, which 
are episodic and known as mood episodes; these disorders are less common than 
major depression but are linked with increased risk of suicide. Effective targets 
in bipolar disorders for DBS are thought to be SCC, the nucleus accumbens, and 
slMFB, but studies are less [68].
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8.4 Obsessive: compulsive disorder
Obsessive–compulsive disorder (OCD) is a debilitating psychological condi-
tion, which is characterized by obsessions combined with time-consuming and 
subjectively anxiolytic behaviors. Several targets were proposed for OCD treat-
ment, but STN DBS was found to be the most effective with significant reduction in 
OCD symptoms [69].
8.5 Anorexia nervosa
Anorexia nervosa is a severe, prevalent, and has one of the highest mortalities 
among any psychiatric disorder. The limbic and emotional circuits are involved 
activating and upholding the disorder. The limited availability of treatment in refractory 
anorexia nervosa and positive outcomes of DBS in mood-related circuits have led the 
curiosity for DBS targets availability in anorexia nervosa condition. Several research 
articles are published on SCC DBS target with significant reduction in depression and 
anxiety [70]. However, further studies are needed for convincing target for DBS.
9. Pain
For patients with pain, the analysis of DBS outcome is more challenging than 
in motor movement disorders due to rationality of pain self-assessment. Though 
nociceptive pain can usually be kept in check with opiate medication, DBS targets in 
the thalamus or cingulum are considered for patients with severe refractory neuro-
pathic pain [30, 71, 72].
10. Positive influence of the DBS treatment
There are a number of side effects via medication that is highly reduced by 
neuromodulation technique. Seizure frequencies and mortality were decreased, but 
the results were not evaluated. Successful results of DBS on movement disorder and 
vagal nerve stimulation for epilepsy [73, 74]. DBS is a best way to treat extrapyra-
midal motor disorder namely dyskinesia, tremors, rigidity, and dystonia [75–77]. 
GPi-DBS, in primary generalized dystonia, was proved to be very successful, and 
it can be used as an effective treatment option [78]. Although with mild treatment 
side effects, a number of studies have shown positive treatment outcome in chronic 
disorders of consciousness with unknown mechanism of action [79]. DBS is found 
to beneficial in enhancing altered learning and memory. In rodents’ model of 
dementia, mesial temporal DBS has shown positive results. Improvement in visual 
memory is seen in patients who underwent unilateral amygdalohippocampal DBS 
[80]. DBS helps in regaining of learning, memory, and altered communication skills 
in patients of postbrain injury with disorders of consciousness [81].
11. Negative influence of the treatment
Severe harmful effects of DBS are seen on dominant side of hippocampal region. 
Bilateral hippocampal DBS may cause memory dysfunction in epilepsy patients. 
Though DBS, is supposed to be safe, the adverse events can be seen in 7.5–8.5% of 
patients. The major adverse effects being, infections, intraoperative seizures and 
other complications [7].
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12. Evolution in DBS technologies
Evolutions in technologies have led to the advancement in pain management in 
DBS. Several technologies related to spinal cord stimulation like Expanded MRI 
labeling, pulse modifier (generator as well as shrinker), dorsal root ganglia stimu-
lating leads, and so on have benefited a lot due to high-frequency and high-density 
strategies of software [82–85]. The major problem in DBS is the inappropriate dose, 
for which no new technology has been developed for the past two decades; there-
fore, there is lack of competitiveness in DBS technology [30].
13. Summary
DBS is a neurosurgical procedure that utilizes lead-implanted electrodes 
that is placed chronically in the target areas of the brain well connected to 
pulse generator, which excites the neuronal circuits [1, 4, 5]. It is an invasive 
neuromodulation technique that was emanated in early 1960s [1]. Recently, DBS 
has become a huge practice in treatment of various movement disorders along 
with some psychiatric disorders [4, 5]. As compared to other neurosurgical 
options, lower chances of complications are seen with this technique [5]. 
Although with mild treatment side effects, a number of studies have shown 
positive  treatment outcome in chronic disorders of consciousness with unknown 
mechanism of action [79]. Growth in DBS in respect to pathway and its impact on 
neuronal circuit has been mainly propelled by preclinical, neurophysiological, and 
computational research. Significant needs and prospect have evolved innovative 
techniques and technologies that have improved tolerability as well as research 
design, but DBS is still growing in many areas to manage cerebral diseases safely 
and efficiently.
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DBS deep brain stimulation
VNS vagal nerve stimulation
TMS transcranial magnetic stimulation
SCS spinal cord stimulation
rTMS repetitive transcranial magnetic stimulation
AD Alzheimer’s disease
NMDA N-methyl-d-aspartate
GPi-DBS globus pallidus internus deep brain stimulation
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